Syntax Bio has expanded its Series A financing to $14.4 million, bringing the Chicago-based synthetic biology company’s total funding to more than $25 million. The company develops stem cell-derived therapies and organoids using its Cellgorithm platform, a CRISPR-based system intended to program and accelerate cellular differentiation. The additional capital is earmarked for further platform development and for advancing a pancreatic beta cell therapy for type 1 diabetes through preclinical proof of concept.
Financing Broadens the Investor Base
The expanded round continues support from Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansueto Office and Portal Innovations. New participants include Draper Associates, Allegis Capital, LongGame, Mayo Clinic, Illinois Ventures, the Illinois Department of Commerce and Economic Opportunity, Exit Fund, Sigma Group and Walder Ventures. The mix of returning and incoming backers provides Syntax Bio with additional resources as it moves from platform validation toward development work on therapeutic candidates and external collaborations.
Cellgorithm Targets a Manufacturing Constraint
Syntax Bio’s technology is designed to control gene activity in sequence, seeking to reproduce elements of human development in the production of functional cell types. The company argues that this approach could replace slower and more variable differentiation processes with a more repeatable system, potentially improving the speed and scalability of cell therapy discovery and manufacturing. Its stated focus is not limited to a single disease area, with the platform positioned for use in regenerative medicine programs and organoid development as well as internal therapeutic pipelines.
Type 1 Diabetes Is the First Therapeutic Focus
The financing will support the company’s pancreatic beta cell program, which seeks to develop an allogeneic treatment for insulin-dependent type 1 diabetes. Syntax Bio announced a research and development collaboration with Mayo Clinic on June 9 to help define and develop stem cell-derived pancreatic cell therapies based on patient needs. The company has also received an award of up to $856,250 from Breakthrough T1D and reported peer-reviewed Science Advances research on its CRISPR-based platform, providing additional support for its scientific and translational agenda.
Executive Changes Align Scientific and Technical Roles
Alongside the funding, co-founder Ryan Clarke has moved from chief technology officer to chief scientific officer, where he will oversee scientific strategy and stem cell therapy innovation. Co-founder Nikolas Balanis has been appointed chief technology officer and will lead further development of the synthetic biology platform and the company’s AI-driven computational biology capabilities. Both executives will report to chief executive John Craighead, who joined Syntax Bio in 2025, while co-founder Brad Merrill remains head of innovation.
New Board and Advisory Appointments Add Experience
Syntax Bio has also appointed Doug Doerfler and Pete Bodine to its board of directors, adding experience in biotechnology company building, investment and operational scaling. Doerfler previously founded and led MaxCyte as chief executive, while Bodine is a managing director at Allegis Capital with a long record of advising early-stage technology companies. Melissa Carpenter and Everett Meyer have joined the scientific advisory board, bringing expertise in stem cell biology, regenerative medicine, cellular therapy, translational science and manufacturing.
The expanded Series A gives Syntax Bio more funding and a broader leadership structure as it pursues a difficult path from programmable cell biology to clinical development. Its near-term progress will depend on whether Cellgorithm can translate its stated differentiation and manufacturing advantages into reliable preclinical results, particularly in the pancreatic beta cell program. With new investors, advisors and collaborators in place, the company is positioning its platform for the next stage of regenerative medicine development.